Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates GlobeNewswire - Thu Mar 5, 6:00AM CST

Initiation of Phase 3 MASH trial planned for 2026 Pemvidutide granted FDA Breakthrough Therapy Designation in MASH Topline data from RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder...

ALT : 3.50 (-0.28%)
Altimmune to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Mar 2, 6:30AM CST

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today...

ALT : 3.50 (-0.28%)
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 GlobeNewswire - Thu Feb 26, 6:30AM CST

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced...

ALT : 3.50 (-0.28%)
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock GlobeNewswire - Thu Jan 29, 4:54PM CST

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.50 (-0.28%)
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock GlobeNewswire - Tue Jan 27, 8:25PM CST

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced...

ALT : 3.50 (-0.28%)
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH GlobeNewswire - Mon Jan 5, 6:30AM CST

GAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced...

ALT : 3.50 (-0.28%)
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial GlobeNewswire - Fri Dec 19, 2025

Improvements observed in key  non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint Additional weight loss from 24 to 48 weeks...

ALT : 3.50 (-0.28%)
Altimmune Announces CEO Transition and Succession Plan GlobeNewswire - Mon Dec 1, 2025

Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01,...

ALT : 3.50 (-0.28%)
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Wed Nov 26, 2025

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic...

ALT : 3.50 (-0.28%)
Metabolic Reset: Cell Therapies and Novel Drugs Reshape Chronic Disease Market BayStreet.ca - Tue Nov 18, 2025

VANCOUVER – Baystreet.ca News Commentary – The metabolic disorder therapeutics market projects growth to $120.7 billion by 2030 as biotechnology firms pioneer organ-level treatments addressing diabetes,...

AVAI : 0.3158 (-1.31%)
TNDM : 20.61 (+2.59%)
CRNX : 41.00 (+5.07%)
MDGL : 532.02 (+1.38%)
ALT : 3.50 (-0.28%)

Barchart Exclusives

Only 3 Dividend Kings Passed This Brutal Screen. They Could Pay You Well for Years to Come. Barchart - Fri Apr 17, 6:00PM CDT
Three Dividend Kings with 50+ years of raises combine reliable income, solid growth, and analyst support, making them stand out in a shaky market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.